Lunit Inc (328130)

Currency in KRW
17,180
-720(-4.02%)
Closed·
328130 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
16,77018,030
52 wk Range
15,33340,750
Key Statistics
Bid/Ask
17,180.00 / 17,190.00
Prev. Close
17,900
Open
17,790
Day's Range
16,770-18,030
52 wk Range
15,333-40,750
Volume
647.97K
Average Volume (3m)
397.09K
1-Year Change
-24.7279%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
328130 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
12,000
Downside
-30.15%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with high price volatility

Lunit Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

0 Buy
0 Hold
1 Sell
Ratings:
1 analysts
Overall Consensus
Strong Sell

Analysts 12-Month Price Target:

Average 12,000
(-30.15% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
12-05-2026
EPS / Forecast
-- / --
Revenue / Forecast
24B / --
EPS Revisions
Last 90 days

328130 Income Statement

Compare 328130 to Peers and Sector

Metrics to compare
328130
Peers
Sector
Relationship
P/E Ratio
−19.8x−2.1x−0.5x
PEG Ratio
0.510.030.00
Price/Book
10.7x1.3x2.6x
Price / LTM Sales
15.2x3.7x3.1x
Upside (Analyst Target)
−33.0%54.4%53.2%
Fair Value Upside
Unlock25.1%6.2%Unlock

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; and with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
3.58M4.82%64.15B
Other Institutional Investors
3.84M5.16%68.68B
Public Companies & Retail Investors
66.95M90.02%1.20T
Total
74.37M100.00%1.33T

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Guardant Health, Inc.3.09%23,00,0004,11,70,000
The Vanguard Group, Inc.2.52%18,72,5083,35,17,893

FAQ

What Is the Lunit (328130) Share Price Today?

The Lunit share price today is 17,180.

What is the current Lunit (328130) share price and day range?

As of 27-05-2026, the Lunit share price is 17,180, with a previous close of 17,900. The share price has ranged from 16,770 to 18,030 today, while the 52-week range spans from 15,333 to 40,750.

What Is the Lunit Market Cap?

As of today, Lunit market cap is 1.33T.

What Is the Lunit (328130) Share Price Target?

The average 12-month share price target for Lunit is 12,000, with a high estimate of 12000 and a low estimate of 12000. 0 analysts recommend buying, while 1 suggest selling, with an overall rating of Strong Sell and -30.15% Downside potential.

What Is Lunit's Earnings Per Share (TTM)?

The Lunit EPS (TTM) is -1,907.

When Is the Next Lunit Earnings Date?

Lunit will release its next earnings report on 07-08-2026.

From a Technical Analysis Perspective, Is 328130 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

What Stock Exchange Does Lunit Trade On?

Lunit is listed and trades on the KOSDAQ.

What Is the Stock Symbol for Lunit?

The stock symbol for Lunit is "328130."

How Many Times Has Lunit Stock Split?

Lunit has split 2 times.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.